Jennifer Gregg, PhD | Authors


Moving Forward: Examining the Evolving Role of Embolization in HCC

April 19, 2016

Despite the widespread prevalence of hepatocellular carcinoma (HCC), effective treatment options for both primary and secondary liver tumors have remained elusive, as these tumors are difficult to manage, especially in cases where the tumor is unresectable.

New Approaches to the Detection and Treatment of HCC With Portal Vein Thrombosis

April 19, 2016

The hepatic portal vein is critical to normal liver function and supplies approximately 75% of the blood supply to the liver. In the general population, portal vein thrombosis (PVT) is relatively rare, occurring with an incidence of about in 1 in 100,000 people.

Novel Therapies on the Horizon in Hepatocellular Carcinoma

April 19, 2016

Both in the United States and worldwide, the incidence of hepatocellular carcinoma (HCC) is on the rise, and, despite extensive research, sorafenib (Nexavar) remains the only FDA-approved systemic therapy available for advanced tumors.